Evidence map›Paper›PMID 26984415›Full record

ReviewCurrent oncology reports2016

Pathology and Surgical Treatment of High-Grade Pancreatic Neuroendocrine Carcinoma: an Evolving Landscape.

Sven-Petter Haugvik, Daniel Kaemmerer, Sebastien Gaujoux, Knut Jørgen Labori, Caroline Sophie Verbeke, Ivar Prydz Gladhaug

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current oncology reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Pancreatic neuroendocrine tumors.Intractable & rare diseases research · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 3 countries.

Sven-Petter HaugvikDepartment of Hepato-Pancreato-Biliary Surgery, Oslo University Hospital, Rikshospitalet, Postbox 4950, Nydalen, 0424, Oslo, Norway. svhaug@ous-hf.no.
Daniel KaemmererDepartment of General and Visceral Surgery, Zentralklinik Bad Berka, Robert-Koch-Allee 9, Bad Berka, 99437, Germany.
Sebastien GaujouxDepartment of Digestive and Endocrine Surgery, Cochin Hospital, APHP, Université Paris Descartes, 27, rue du Faubourg Saint Jacques, 74014, Paris, France.
Knut Jørgen LaboriDepartment of Hepato-Pancreato-Biliary Surgery, Oslo University Hospital, Rikshospitalet, Postbox 4950, Nydalen, 0424, Oslo, Norway.
Caroline Sophie VerbekeInstitute of Clinical Medicine, University of Oslo, Postbox 1171, Blindern, 0318, Oslo, Norway.
Ivar Prydz GladhaugDepartment of Hepato-Pancreato-Biliary Surgery, Oslo University Hospital, Rikshospitalet, Postbox 4950, Nydalen, 0424, Oslo, Norway.
University of Oslo · NOOslo University Hospital · NOUniversité Paris Cité · FRZentralklinik Bad Berka · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic neuroendocrine neoplasms (PNENs) are rare, accounting for less than 5% of all pancreatic tumors. High-grade pancreatic neuroendocrine carcinomas (hgPNECs) represent about 5% of all PNENs. They show highly aggressive behavior with dismal prognosis. Throughout the last two decades, there has been a notable progress in basic and clinical research of PNENs and a therapeutic trend towards both more aggressive and minimally invasive surgery. Despite these advances, hgPNECs as a distinct clinical entity remains largely unexplored among surgeons. This review of current development in pathology reporting and surgical treatment of hgPNECs aims at increasing the awareness of an evolving field in pancreatic surgery.

Indexed as

Biomarkers, TumorCarcinoma, NeuroendocrineHumansKi-67 AntigenMitotic IndexNeoplasm GradingPancreatic NeoplasmsPrognosisSurvival AnalysisTreatment OutcomeBiomarkers, TumorKi-67 AntigenGastroenteropancreatic neuroendocrine tumorNeuroendocrine carcinomaNeuroendocrine neoplasmNeuroendocrine tumorPancreasPancreatic cancerPancreatic neoplasmPancreatic surgeryReview

Identifiers

PMID26984415
OpenAlexW2300365513

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.